Fractyl Health, Inc. Common Stock (GUTS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Fractyl Health, Inc. Common Stock stock (GUTS) is currently trading at $0.50. Fractyl Health, Inc. Common Stock PS ratio (Price-to-Sales) is 22561.03. Analyst consensus price target for GUTS is $5.24. WallStSmart rates GUTS as Sell.
- GUTS PE ratio analysis and historical PE chart
- GUTS PS ratio (Price-to-Sales) history and trend
- GUTS intrinsic value — DCF, Graham Number, EPV models
- GUTS stock price prediction 2025 2026 2027 2028 2029 2030
- GUTS fair value vs current price
- GUTS insider transactions and insider buying
- Is GUTS undervalued or overvalued?
- Fractyl Health, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- GUTS Piotroski F-Score and Altman Z-Score
- GUTS analyst price target and Smart Rating
Fractyl Health, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Fractyl Health, Inc. Common Stock (GUTS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Fractyl Health, Inc. Common Stock (GUTS) Key Strengths (2)
77.50% of shares held by major funds and institutions
Trading at 1.86x book value, attractively priced
Supporting Valuation Data
Fractyl Health, Inc. Common Stock (GUTS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -57.10%, a shrinking business
Very expensive at 22561.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Fractyl Health, Inc. Common Stock (GUTS) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.86) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (22561.03) suggest expensive pricing. Growth concerns include Revenue Growth at -57.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -518.00%, Operating Margin at -3291400.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -518.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -57.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GUTS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GUTS's Price-to-Sales ratio of 22561.03x sits near its historical average of 24046.55x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 13% below its historical high of 25827.85x set in Mar 2026, and 0% above its historical low of 22561.03x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Fractyl Health, Inc. Common Stock (GUTS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Fractyl Health, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 3,000 with 57% decline year-over-year.
Key Findings
Debt-to-equity ratio of -19.57 indicates a conservative balance sheet with 78M in cash.
Spending 581900% of revenue (17M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 57% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -23M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.51, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Fractyl Health, Inc. Common Stock.
Bottom Line
Fractyl Health, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Fractyl Health, Inc. Common Stock(GUTS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company is headquartered in Lexington, Massachusetts.